Clinical Trial Update: A Study to Investigate Tolerability and Efficacy of Asciminib (Oral) Versus Nilotinib (Oral) in Adult Participants (≥18 Years of Age) With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia in Chronic Phase (Ph+ CML-CP) [Phase 3]

View source ↗

Summary

Phase 3 trial comparing Asciminib to Nilotinib in adults with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase, assess…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Myeloid Leukemia

Drugs mentioned

• Asciminib (asciminib)
• Nilotinib (nilotinib)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Philadelphia Chromosome-Positive Chronic Myeloid Leukemia | Phase 3 | Status: ACTIVE_NOT_RECRUITING